Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Via Pansini 5, 80131 Naples, Italy.
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands.
Cells. 2022 Mar 10;11(6):940. doi: 10.3390/cells11060940.
Cell reprogramming is a groundbreaking technology that, in few decades, generated a new paradigm in biomedical science. To date we can use cell reprogramming to potentially generate every cell type by converting somatic cells and suitably modulating the expression of key transcription factors. This approach can be used to convert skin fibroblasts into pluripotent stem cells as well as into a variety of differentiated and medically relevant cell types, including cardiomyocytes and neural cells. The molecular mechanisms underlying such striking cell phenotypes are still largely unknown, but in the last decade it has been proven that cell reprogramming approaches are significantly influenced by non-coding RNAs. Specifically, this review will focus on the role of microRNAs in the reprogramming processes that lead to the generation of pluripotent stem cells, neurons, and cardiomyocytes. As highlighted here, non-coding RNA-forced expression can be sufficient to support some cell reprogramming processes, and, therefore, we will also discuss how these molecular determinants could be used in the future for biomedical purposes.
细胞重编程是一项具有开创性的技术,在短短几十年内就在生物医学科学中产生了一种新的范例。迄今为止,我们可以通过重编程体细胞并适当调节关键转录因子的表达来潜在地产生所有类型的细胞。这种方法可用于将皮肤成纤维细胞转化为多能干细胞以及多种分化和与医学相关的细胞类型,包括心肌细胞和神经细胞。这种惊人的细胞表型背后的分子机制在很大程度上仍然未知,但在过去十年中已经证明,细胞重编程方法受到非编码 RNA 的显著影响。具体而言,本综述将重点介绍 microRNAs 在重编程过程中的作用,这些过程导致多能干细胞、神经元和心肌细胞的产生。如本文所强调的,非编码 RNA 强制表达足以支持一些细胞重编程过程,因此,我们还将讨论这些分子决定因素将来如何用于生物医学目的。
Cells. 2022-3-10
Stem Cell Rev Rep. 2018-2
Acc Chem Res. 2017-4-28
Mol Neurobiol. 2017-3
J Cell Sci. 2012-10-17
J Mol Med (Berl). 2012-6-9
Ibrain. 2025-1-4
Adv Exp Med Biol. 2025
J Transl Med. 2025-2-27
Int J Mol Sci. 2024-7-24
BMC Musculoskelet Disord. 2024-1-2
Stem Cells Transl Med. 2023-5-15
Int J Mol Sci. 2021-9-1
Semin Cell Dev Biol. 2022-2
Adv Drug Deliv Rev. 2021-7